43 results
8-K
EX-99.1
NDRA
ENDRA Life Sciences Inc
6 Jun 24
ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering
8:00am
assessment of fatty tissue in the liver. Steatotic liver disease (SLD, formerly known as NAFLD-NASH) is a chronic liver disease spectrum that affects over
8-K
EX-99.1
NDRA
ENDRA Life Sciences Inc
20 May 24
ENDRA Provides Update Following In-person Meeting with FDA
8:05am
of fatty tissue in the liver. Steatotic liver disease (SLD, formerly known as NAFLD-NASH) is a chronic liver disease spectrum that affects over two
8-K
EX-99.1
NDRA
ENDRA Life Sciences Inc
14 May 24
ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update
4:17pm
of fat in the liver as a means to assess and monitor steatotic liver disease (SLD) (formerly known as NAFLD-NASH), a chronic liver disease spectrum
8-K
EX-99.1
NDRA
ENDRA Life Sciences Inc
28 Mar 24
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:10pm
to assess and monitor steatotic liver disease (SLD) (formerly known as NAFLD-NASH), a chronic liver disease spectrum that affects over two billion people
8-K
EX-99.1
r47iwbz0fpl
14 Nov 23
ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
4:02pm
8-K
EX-99.1
ag30p685msckyb3pafp
14 Aug 23
ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update
4:13pm
8-K
EX-99.2
68ykvuy2
14 Aug 23
ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update
4:13pm
8-K
EX-99.1
yot2q8cqh4opjxl
6 Jul 23
ENDRA Life Sciences Announces Adjournment of
5:25pm
DEFA14A
EX-99.1
xygq 7vriu7geqbag
6 Jul 23
Additional proxy soliciting materials
5:25pm
8-K
EX-99.1
ohlr9l2t mls
15 May 23
ENDRA Life Sciences Reports First Quarter 2023 Financial Results and Provides a Business Update
12:00am
8-K
EX-99.1
6ng0rzpgz ovf
2 May 23
ENDRA Life Sciences Announces Pricing of Upsized $4.5 Million Public Offering
4:16pm
8-K
EX-99.2
v3frc
2 May 23
ENDRA Life Sciences Announces Pricing of Upsized $4.5 Million Public Offering
4:16pm
8-K
EX-99.1
tpdj8 6fzey4
14 Nov 22
ENDRA Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
4:32pm
8-K
EX-99.1
rzsk6so39o u8qrpo
15 Aug 22
ENDRA Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
5:17pm
8-K
EX-99.1
xcp39gdj ve184p
12 May 22
ENDRA Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
4:06pm
8-K
EX-99.1
205olp ogsdy
21 Apr 22
Regulation FD Disclosure
8:08am
8-K
EX-99.1
ksldf2vjqi3po16430
30 Mar 22
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
4:11pm
8-K
EX-99.1
tubxuk3plbj5bz1
10 Feb 22
ENDRA Life Sciences Provides Update on U.S. Regulatory Strategy for its TAEUS® System
8:00am